Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 6 of 23, showing 5 Applications out of 114 total, starting on record 26, ending on 30

# Protocol No Study Title Investigator(s) & Site(s)

26.

ECCT/23/02/01   Hibiscus Kid\'s Study
    A Single Arm, Open Label, Phase 1/2 Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients with Sickle Cell Disease   
Principal Investigator(s)
1. Videlis Nduba
2. Walter Otieno
3. Isaac Tsikhutsu
Site(s) in Kenya
1. AHERO CLINICAL TRIALS UNIT (Kisumu county)
2. KEMRI-Walter Reed-Kericho (Kericho county)
3. KEMRI: Siaya Clinical Research Annexe (Kisumu county)
4. Kombewa Clinical Research Centre (Kisumu county)
 
View

27.

ECCT/22/10/05   Agios Study
    A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease. Mitapivat - AG348-C-020   
Principal Investigator(s)
1. Videlis N Nduba
Site(s) in Kenya
1. KEMRI/CRDR (Nairobi City county)
2. KEMRI Siaya Clinical Research Annex (Siaya county)
 
View

28.

ECCT/22/10/02   Agios Study
    A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease. Mitapivat - AG348-C-020   
Principal Investigator(s)
1. Janet N Oyieko
Site(s) in Kenya
1. Kombewa Clinical Research Centre (Kisumu county)
2. Victoria Biomedical Research Institute (Kisumu county)
3. KEMRI/CRDR (Nairobi City county)
4. KEMRI Siaya Clinical Research Annex (Siaya county)
5. Gertrude’s Children’s Hospital (Nairobi City county)
6. KEMRI Kondele Children\'s Hospital (Kisumu county)
7. Strathmore University Medical Centre (Nairobi City county)
 
View

29.

ECCT/22/08/02   AIM-LVRNA009-II_III-01
    A Global Multi-center, Randomized, Blinded, Placebo-controlled Phase 2/3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (LVRNA009) for the Prevention of COVID-19 in Participants Aged 18 Years and Olde   
Principal Investigator(s)
1. Bernhards Ogutu
2. Lucas Otieno
3. Videlis Nduba
4. Bernhards Ogutu
5. Jacqueline Mirera
6. Jacqueline Mirera
Site(s) in Kenya
1. Siaya Clinical Trials Unit (Siaya county)
2. Homa Bay Clinical Trials Unit (Homa Bay county)
3. Ahero Clinical Trials Unit (Kisumu county)
4. CREA-N Machakos (Machakos county)
5. CREA-N Nakuru (Nakuru county)
6. Victoria Biomedical Research Institue (Kisumu county)
 
View

30.

ECCT/22/09/01   Agios Study
    A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease. Mitapivat - AG348-C-020   
Principal Investigator(s)
1. Bernhards Ragama Ogutu
2. Godfrey Allan Otieno
Site(s) in Kenya
1. Strathmore University Medical Centre (Nairobi City county)
2. Victoria Biomedical Research Institute (Kisumu county)
3. KEMRI/CRDR (Nairobi City county)
4. KEMRI Siaya Clinical Research Annex (Siaya county)
5. Gertrude’s Children’s Hospital (Nairobi City county)
6. KEMRI Kondele Children\'s Hospital (Kisumu county)
7. Kombewa Clinical Research Centre (Kisumu county)
 
View